Monday, August 19, 2013 10:55:26 PM
From Jason N. August 15th:
However, the biggest catalyst on the horizon is the pending ODD decision by the U.S. FDA, expected in October or November 2013. A positive decision on this front has the potential to double the shares, and lead to a partnership for KRN5500 from a larger pharmaceutical company that could bring in significant upfront cash. With this cash, Dara can funnel money back to increasing the market and promotion around Soltamox and Gelclair.
http://seekingalpha.com/article/1638362-patience-required-for-dara-bio-investment
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM